Stick with the treatment plan from your healthcare provider, and youll be back in action in no time
Clinical trials for CagriSema began in November 2022 and are projected to run through October 2026, with the drug administered under the skin once weekly
S., Armutcu, F., Sahin, S
The FDA classifies it as a Category 2 bulk drug substance, noting potential safety concerns in unregulated compounding
Some clinical trials have suggested that NAC supplementation may improve liver enzymes, insulin sensitivity, and markers of liver inflammation in patients with NAFLD, though the evidence base remains insufficient for clinical recommendations
Standard beginner protocols typically involve 1-2 mg administered subcutaneously 2-3 times per week, with most researchers running 8-12 week cycles followed by 4-6 week breaks